Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

pierre fabre pharma norden ab - vinorelbinum tvítartrat - mjúkt hylki - 20 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

medical valley invest ab - aprepitantum inn - hart hylki - 125 mg + 80 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

bluefish pharmaceuticals ab - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

stada arzneimittel ag - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

actavis group ptc ehf. - oxaliplatinum inn - innrennslisþykkni, lausn - 5 mg/ml

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 4 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ondansetronum hýdróklóríð - filmuhúðuð tafla - 8 mg

Islandija - islandų - LYFJASTOFNUN (Icelandic Medicines Agency)

sandoz a/s - ondansetronum hýdróklóríð - mixtúra, lausn - 0,8 mg/ml

Europos Sąjunga - islandų - EMA (European Medicines Agency)

les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - Æxlishemjandi lyf - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.